News | February 28, 2023
Sanofi reaffirms commitment to rare diseases in India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Twelve hospitals across India will be part of the network which will support the trial in India
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
N-nitroso dimethylamine (NDMA) is a probable human carcinogen and tts effects on humans rely on observational studies.
Clinical studies are expected to start in Q2 2023.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
Ayurveda is one of the most advanced sciences of its times
Subscribe To Our Newsletter & Stay Updated
